{"url_path":"/sec/evfm/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1618835/0001493152-26-023928-index.html","accession_number":"0001493152-26-023928","cik":"0001618835","ticker":"EVFM","issuer_name":"Evofem Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1618835/0001493152-26-023928-index.html","primary_entity_key":"0001618835","primary_entity_name":"Evofem Biosciences, Inc."},"word_count":493,"has_tables":true,"body_markdown":"**Item\n6. Exhibits**\n\n \n\nThe\nexhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index.\n\n \n\n**EXHIBIT\nINDEX**\n\n \n\n**Exhibit**\n \n \n \n**Filed**\n \n**Incorporated\nby Reference**\n\n**No.**\n \n**Exhibit\nTitle**\n \n**Herewith**\n \n**Form**\n \n**File\nNo.**\n \n**Date\nFiled**\n\n10.1\n \n[Termination Agreement between the Company and Windtree Therapeutics, Inc. dated March 13, 2026](https://www.sec.gov/Archives/edgar/data/1618835/000149315226011613/form8-k.htm)\n \n \n \n8-K\n \n001-36754\n \n3/19/2026\n\n10.2\n \n[Fourth Amendment to Securities Purchase Agreement dated as of April 10, 2026](https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/ex10-1.htm)\n \n \n \n8-K\n \n001-36754\n \n4/16/2026\n\n10.3\n \n[Exclusive Distributorship Agreement dated as of April 24, 2026](https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/ex10-1.htm)\n \n \n \n8-K\n \n001-36754\n \n4/30/2026\n\n31.1\n*\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm)\n \nX\n \n \n \n \n \n \n\n31.2\n*\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-2.htm)\n \nX\n \n \n \n \n \n \n\n32.1\n*\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n \nX\n \n \n \n \n \n \n\n101.INS\n†\nInline\nXBRL Instance Document\n \nX\n \n \n \n \n \n \n\n101.SCH\n†\nInline\nXBRL Taxonomy Extension Schema Document\n \nX\n \n \n \n \n \n \n\n101.CAL\n†\nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n \nX\n \n \n \n \n \n \n\n101.DEF\n†\nInline\nXBRL Definition Linkbase Document\n \nX\n \n \n \n \n \n \n\n101.LAB\n†\nInline\nXBRL Taxonomy Extension Labels Linkbase Document\n \nX\n \n \n \n \n \n \n\n101.PRE\n†\nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n \nX\n \n \n \n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n \nX\n \n \n \n \n \n \n\n \n\n*\nFurnished\nherewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any\nfiling of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language\nin such filing.\n\n†\nThe\nfinancial information of Evofem Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed on May\n15, 2026 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) Parenthetical\nData to the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Operations, (iv) the Condensed\nConsolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders’ Deficit, (v) the Condensed Consolidated\nStatements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, is furnished electronically herewith.\n\n^^\nCertain\nexhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally\na copy of any omitted exhibit or schedule upon request by the SEC.\n\n \n\n53\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**EVOFEM\nBIOSCIENCES, INC.**\n\n \n \n \n\nDate:\nMay 15, 2026\nBy:\n*/s/\nIvy Zhang*\n\n \n \nIvy\nZhang\n\n \n \n\nChief\nFinancial Officer\n\n(Principal\nFinancial Officer and Principal Accounting Officer)\n\n \n\n54"}